Indian Journal of Medical Research

REVIEW ARTICLE
Year
: 2020  |  Volume : 151  |  Issue : 1  |  Page : 22--34

The need & the issues related to new-generation typhoid conjugate vaccines in India


Vipin M Vashishtha1, Ajay Kalra2 
1 Mangla Hospital & Research Center, Bijnor, Uttar Pradesh, India
2 Department of Pediatrics, Sarojini Naidu Medical College, Agra, Uttar Pradesh, India

Correspondence Address:
Dr Vipin M Vashishtha
Mangla Hospital & Research Center, Shakti Chowk, Bijnor 246 701, Uttar Pradesh
India

The low- and middle-income countries bear the highest burden of typhoid fever in the world. India, along with other South Asian countries, has a significant incidence of typhoid fever among young children though there is a paucity of published data on community burden. In spite of the availability of Vi-polysaccharide (Vi-PS) and conjugated Vi-PS vaccines, these are not adequately utilized in India and in the neighbouring countries. To address many shortcomings of the unconjugated Vi-PS vaccines, typhoid conjugate vaccines (TCVs) are developed by conjugating Vi-PS with different carrier proteins. Three such vaccines using tetanus toxoid as a carrier protein are already licensed in India. Several other Vi-PS conjugates are currently in various stages of development. The current review provides an update on the existing and upcoming new TCVs along with a detailed discussion on the various issues involved with their clinical use and limitations.


How to cite this article:
Vashishtha VM, Kalra A. The need & the issues related to new-generation typhoid conjugate vaccines in India.Indian J Med Res 2020;151:22-34


How to cite this URL:
Vashishtha VM, Kalra A. The need & the issues related to new-generation typhoid conjugate vaccines in India. Indian J Med Res [serial online] 2020 [cited 2020 Jul 3 ];151:22-34
Available from: http://www.ijmr.org.in/article.asp?issn=0971-5916;year=2020;volume=151;issue=1;spage=22;epage=34;aulast=Vashishtha;type=0